- Reply Letter to “Cervical Facet Joint Degeneration”
-
Takeshima Y, Okamoto A, Yokoyama S, Nishimura F, Nakagawa I, Park YS, Nakase H
- KMID: 2533811
- Neurospine.
- 2022 Sep;19(3):851-852.
- doi: 10.14245/ns.2244654.327
-
- CITED
-
- Close
- SHARE
-
- Close
- Blood Levels of Ammonia and Carnitine in Patients Treated with Valproic Acid: A Meta-analysis
-
Yokoyama S, Sugawara N, Maruo K, Yasui-Furukori N, Shimoda K
- KMID: 2532818
- Clin Psychopharmacol Neurosci.
- 2022 Aug;20(3):536-547.
- doi: 10.9758/cpn.2022.20.3.536
Objective: Long-term valproic acid (VPA) administration is associated with adverse metabolic effects, including hyperammonemia and hypocarnitinemia. However, the pathogeneses of these adverse events remain unclear, and not enough reviews have... -
- CITED
-
- Close
- SHARE
-
- Close
- Prevalence and Clinical Impact of Cervical Facet Joint Degeneration on Degenerative Cervical Myelopathy: A Novel Computed Tomography Classification Study
-
Okamoto A, Takeshima Y, Yokoyama S, Nishimura F, Nakagawa I, Park YS, Nakase H
- KMID: 2531551
- Neurospine.
- 2022 Jun;19(2):393-401.
- doi: 10.14245/ns.2143258.629
Objective: To evaluate cervical facet joint degeneration using a newly developed classification, investigate its prevalence and relationship with cervical degenerative spondylolisthesis, and clarify its clinical significance in patients with degenerative... -
- CITED
-
- Close
- SHARE
-
- Close
- Facet Articular Irregularity Is the Most Relevant Risk Factor for Rapidly Progressive Degenerative Cervical Myelopathy
-
Takeshima Y, Okamoto A, Yokoyama S, Nishimura F, Nakagawa I, Park YS, Nakase H
- KMID: 2540901
- Neurospine.
- 2023 Mar;20(1):365-373.
- doi: 10.14245/ns.2245004.502
Objective: Facet articular irregularity is associated with rapidly progressive degenerative cervical myelopathy (DCM). However, its significance compared with other known risk factors remains unknown. Therefore, this retrospective study aimed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
-
Nakamura S, Asano T, Tsuchiya H, Sugimoto K, Imai Y, Yokoyama S, Suzuki Y
- KMID: 2531987
- Intest Res.
- 2022 Jul;20(3):329-341.
- doi: 10.5217/ir.2021.00032
Background/Aims: Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness... -
- CITED
-
- Close
- SHARE
-
- Close
- Influence of Repeated Senna Laxative Use on Skin Barrier Function in Mice
-
Yokoyama S, Hiramoto K, Yamate Y, Ooi K
- KMID: 2388938
- Ann Dermatol.
- 2017 Aug;29(4):414-421.
- doi: 10.5021/ad.2017.29.4.414
BACKGROUND: Senna, one of the major stimulant laxatives, is widely used for treating constipation. Chronic senna use has been reported to be associated with colonic disorders such as melanosis coli... -
- CITED
-
- Close
- SHARE
-
- Close
